Literature DB >> 10779409

Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.

H B Wang1, F D Shi, H Li, P H van der Meide, H G Ljunggren, H Link.   

Abstract

Experimental autoimmune myasthenia gravis (EAMG) is caused by autoantibodies against the nicotinic acetylcholine receptor (AChR) at the neuromuscular postsynaptic membrane and represents an animal model of myasthenia gravis in human. Recent studies highlighted the roles of TH1 cytokines (IFN-gamma, IL-12), rather than TH2 cytokines (IL-4), in the pathogenesis of EAMG by using homozygous (-/-) knockout mice with an EAMG-susceptible genetic background. To further evaluate a role for IFN-gamma, we injected recombinant rat IFN-gamma (rrIFN-gamma) at the time of immunization with AChR in complete Freund's adjuvant to EAMG-susceptible Lewis rats and EAMG-resistant Wistar Furth (WF) rats. RrIFN-gamma enhanced Lewis rat EAMG. The exacerbated muscular weakness was associated with higher levels of anti-AChR IgG and enhanced TNF-alpha responses. Anti-AChR IgG antibody levels were augmented to a similar extent as in Lewis rats, however, the identical immunization and IFN-gamma injection induced only mild and transient EAMG in WF rats due to the default TH3 phenotype development and inherent low TH1 responses. We conclude that IFN-gamma plays a major role in the pathogenesis of EAMG in the Lewis rat, but fails to break disease resistance in the WF rat. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779409     DOI: 10.1006/clim.2000.4850

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

1.  Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Authors:  Xiuhua Yao; Qingfei Kong; Xiaoli Xie; Jinghua Wang; Na Li; Yumei Liu; Bo Sun; Ying Li; Guangyou Wang; Wenjin Li; Siying Qu; Haijun Zhao; Dandan Wang; Xijun Liu; Yao Zhang; Lili Mu; Hulun Li
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

2.  Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.

Authors:  Badiga Venkata Aruna; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

3.  Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis.

Authors:  Guoyan Qi; Peng Liu; Shanshan Gu; Hongxia Yang; Huimin Dong; Yinping Xue
Journal:  Neurol Sci       Date:  2018-02-13       Impact factor: 3.307

4.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

5.  IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4.

Authors:  Sabrina Shandley; Sonia Martinez; Keith Krolick
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

Review 6.  Therapeutic vaccines in autoimmunity.

Authors:  Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

7.  Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.

Authors:  Lili Mu; Bo Sun; Qingfei Kong; Jinghua Wang; Guangyou Wang; Shujuan Zhang; Dandan Wang; Yumei Liu; Yixi Liu; Huixia An; Hulun Li
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

8.  MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1.

Authors:  Zhuoan Cheng; Shaobo Qiu; Lin Jiang; Anle Zhang; Wenjing Bao; Ping Liu; Jianwen Liu
Journal:  J Clin Immunol       Date:  2012-11-30       Impact factor: 8.317

9.  Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity.

Authors:  Peng Zhang; Chun-Lin Yang; Tong Du; Yu-Dong Liu; Meng-Ru Ge; Heng Li; Ru-Tao Liu; Cong-Cong Wang; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2021-10-26       Impact factor: 8.322

10.  AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model.

Authors:  Feng Jing; Wei Huang; Qian Ma; Sheng-Jie Xu; Chang-Jin Wu; Yu-Xiu Guan; Bing Chen
Journal:  Med Sci Monit       Date:  2020-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.